Objective parameters analysis
In patients suffering from CM , treatment with erenumab significantly reduced the number of MHD from baseline mean (SD) of 22,09 (7.12) to 17.03 (9.48) after the administration of 3 doses (-5.05; 95% CI: -3.03,-7.07; p<0.01) and to 11.42 (8.44) after 6 doses (-8.27; 95% CI: -5.08,-11.46; p<0.01) (Figure 2A ). Likewise, patients treated with galcanezumab also reported a reduction in MHD from of 20.36 (7.67) to 15.02 (8.70) after the administration of 3 doses (-5.36; 95% CI: -2.97,-7.75; p<0.01) and to 10.69 (8.18) after 6 doses (-8.18; 95% CI: -3.30,-13.06; p<0.01) (Figure 2B ).
Very similar results were observed in patients diagnosed with EM . Erenumab reduced MHD from 15.64 (6.61) at baseline to 9.16 (6.52) after the administration of 3 doses (-6.48; 95% CI: -3.56,-9.4; p<0.01) and to 8.72 (8.16) after 6 doses (-7.50; 95% CI: -2.87,-12.03; p<0.01) (Figure 2C ). Galcanezumab reduced MHD from 14.68 (6.20) at baseline to 9.48 (6.43) after the administration of 3 doses (-5.52; 95% CI: -1.73,-9.31; p<0.01) and to 6.25 (5.21) after 6 doses (-7.69; 95% CI: -3.55,-11.83; p<0.01) (Figure 2D ).
Regarding AMSMD , patients with CM treated with erenumab experienced a reduction from baseline 18.72 (8.48) to 11.91 (8.95) after the administration of 3 doses (-6.82; 95% CI: -4.73,-8.91; p<0.01) and to 8.34 (6.52) after 6 doses (-9.34 day reduction; 95% CI: -6.34,-12.34; p<0.01) (Figure 3A ). Similarly, patients treated with galcanezumab also reported a reduction in AMSMD from of 18.06 (7.57) to 13.03 (9.20) after the administration of 3 doses (-4.30; 95% CI: -1.70,-6.90; p<0.01) and to 11.57 (9.55) after 6 doses (-8.11 day reduction; 95% CI: -2.84,-13.38; p<0.01) (Figure 3B ).
Additionally, erenumab reduced AMSMD in patients with EMfrom baseline 13.88 (4.93) to 7.89 (5.15) after the administration of 3 doses (-5.80; 95% CI: -3.78,-7.82; p<0.01) and to 5.74 (5.18) after 6 doses (-7.89; 95% CI: -5.41,-10.38; p<0.01) (Figure 3C ). Galcanezumab also reduced AMSMD from 11.55 (5.31) at baseline to 8.48 (5.12) after the administration of 3 doses (-3.24; 95% CI: -1.50,-4.98; p<0.01) and to 5.94 (5.38) after 6 doses (-4.88; 95% CI: -3.40,-6.36; p<0.01) (Figure 3D ).